Ascletis Unveils Potent Oral Triple Agonist ASC37 for Obesity Treatment
Ascletis Pharma Inc. has selected ASC37, an oral GLP-1R/GIPR/GCGR triple peptide agonist, for clinical development targeting obesity treatment. ASC37 showed significantly greater potency in preclinical studies compared to retatrutide. The company plans to submit an IND application to the U.S. FDA by Q2 2026. This announcement precedes a conference call on December 1, 2025. The original content was published by Ascletis via the Hong Kong Stock Exchange's Issuer Information Service.
Ascletis Pharma Inc. has announced the selection of ASC37, its first oral GLP-1R/GIPR/GCGR triple peptide agonist, for clinical development. In preclinical studies, ASC37 demonstrated significantly greater in vitro potency-approximately 5-fold for GLP-1R, 4-fold for GIPR, and 4-fold for GCGR-compared to retatrutide. The company plans to submit an Investigational New Drug Application (IND) for ASC37 oral tablets to the U.S. Food and Drug Administration in the second quarter of 2026. These research results have been announced in advance of a planned conference call scheduled for December 1, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251130-11933721), on November 30, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
